Compare Tango Therapeutics Inc. (TNGX) vs Union Pacific Corporation (UNP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tango Therapeutics Inc. vs Union Pacific Corporation — how do they compare? Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B), while Union Pacific Corporation trades at $289.71 (market cap $170.16B). The key difference: Union Pacific Corporation is far larger — about 45.5× Tango Therapeutics Inc.'s market cap, and Union Pacific Corporation pays a 1.98% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Tango Therapeutics Inc. for 0 Days and Union Pacific Corporation for 105 Days on average.
| TNGX | UNP | |
|---|---|---|
Market Cap | $3.74B | $170.16B |
Volume | 3,438,781 | 2,454,439 |
Sector | Health | Industrials |
52-Week High | $32.90 | $310.62 |
52-Week Low | $7.50 | $216.37 |
Typical Hold Time | 0 Days | 105 Days |
Enterprise Value | $2.76B | $199.22B |
Dividend Yield | — | 1.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Union Pacific (UNP) trades at $282.36, up 0.28% today, with strong technical momentum showing bullish moving average signals. The railroad operator demonstrates robust fundamentals with 28.85% net margins and 39.7% ROE, supported by consecutive earnings beats in Q1 and Q2 2026. Recent developments include battery-electric locomotive deployment and progress on the Norfolk Southern combination, while analyst consensus remains strongly bullish with a $332.10 price target.
UNP presents a compelling investment case with pricing power from its irreplaceable rail network and 20-year dividend growth streak. Key opportunities include merger synergies and fuel-cost advantages driving freight from trucks to rail. Risks center on merger approval uncertainty, fuel price volatility impacting operating ratios, and cyclical economic exposure. The stock offers 17.6% upside to consensus target with strong institutional support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →About Union Pacific Corporation
Omaha, Nebraska-based Union Pacific is the largest public railroad in North America. Operating on more than 30,000 miles of track in the western two thirds of the U.S., UP generated roughly $22 billion of revenue in 2021 by hauling coal, industrial products, intermodal containers, agriculture goods, chemicals, and automotive goods. UP owns about one fourth of Mexican railroad Ferromex and derives about 10% of its revenue hauling freight to and from Mexico.
Read more on UNP →
